tbuckley/cabot-search huggingface dataset:
Collaboration needed for HIV vaccine success
Authors: R. Voelker
Journal: JAMA (1997)

A MUCH STRONGER public-private partnership is needed if a safe, effective vaccine against the human immunodeficiency virus (HIV) is going to be developed, says a new report entitled<i>Industry Investment in HIV Vaccine Research</i>. The AIDS Vaccine Advocacy Coalition (AVAC) in San Francisco, Calif, which released the report on World AIDS Day, says working relationships between government and industry have improved in recent years, but many deficits remain. In fact, the report's authors call government leadership the "key ingredient" needed to expedite the creation of a successful vaccine. "We were surprised to learn that, in most cases, government is the engine that drives industry and that industry research depends on government financing, government leadership, and government support," said Chris Collins, MPP, an author of the report and policy specialist at the Center for AIDS Prevention Studies at the University of California at San Francisco. <h3>Baltimore Appointment Hailed</h3> About a week
Pathology of Acute Salt Poisoning in Infants
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Androgen Receptor Expression in the Caput Epididymal Epithelium Is Essential for Development of the Initial Segment and Epididymal Spermatozoa Transit
Authors: Laura O'Hara, Michelle Welsh, Philippa T. K. Saunders, Lee B. Smith
Journal: Endocrine Reviews (2011)

The epididymis plays an essential role in male fertility, and disruption of epididymal function can lead to obstructive azoospermia. Formation and function of the epididymis is androgen-dependent. The androgen receptor (AR) is expressed in both the stromal and epithelial compartments of the epididymis, and androgen action mediated via stromal cells is vital for its normal development and function. However the impact of epithelial specific AR-dependent signaling in the epididymis remains underexplored. To address this, we used conditional gene-targeting in mice to selectively ablate AR from the caput epididymal epithelium, and characterized the resulting phenotype at multiple postnatal ages. Caput epithelium androgen receptor knock-out (CEARKO) mice have normal serum testosterone concentrations at day (d) 21 and d100, but do not develop an epididymal initial segment. The remaining caput epithelium displays a significant decrease in epithelial cell height from d11 and lumen diameter from d21 and disruption of the smooth muscle layer of the caput epididymis at d100. From d21, CEARKO mice accumulate cell debris, proteinaceous material, and, at later ages, spermatozoa in their efferent ducts, which prevents normal passage of spermatozoa from the testis into the cauda epididymis resulting in infertility when tested at d100. This efferent duct obstruction leads to fluid back-pressure and disruption of the seminiferous epithelium of the adult testis. We conclude that epithelial AR signaling is essential for postnatal development and function of the epididymal epithelium and that disruption of this signaling can contribute to obstructive azoospermia.
OZONE AND WATER PURIFICATION.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sarcopenia HIBA score predicts the presence of sarcopenia and mortality in patients on the waiting list for liver transplant
Authors: Ezequiel Mauro, Juan Manuel Diaz, Maria Nelly Gutierrez Acevedo, Lucrecia Garcia Olveira, Fernanda Zalazar, Agustina Martinez Garmendia, Lorena Savluk, Julia Saidman, Jorge Ortiz Patron, Carla Bermudez, Adrian Narvaez, Gonzalo Crespo, Juan Carlos Spina, Adrian Gadano
Journal: Journal of Hepatology (2020)
THE CLEVELAND SESSION
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Failure of low-dose heparin to prevent significant thromboembolic complications in high-risk surgical patients: interim report of prospective trial. Groote Schuur Hospital Thromboembolus Study Group.
Authors: Groote Schuur, E Immelman, P Jeffery, S Benatar, M Elliot, J Smith, R Funston, J Shepstone, A Ferguson, J Pretorius, M Goldacre, B Watt, J Milne, Nancy Loudon
Journal: BMJ (1979)

The efficacy of low-dose subcutaneous heparin (5000 IU eight-hourly) is being studied in a single-centre, prospective randomised trial of patients aged over 40 submitted to major elective intra-abdominal surgery. The trial end-points are the objectively defined incidence and extent of deep vein thrombosis (as seen on uptake of 125I-labelled fibrinogen, Doppler ultrasonography, and bilateral ascending phlebography) and non-fatal pulmonary embolus (as measured by preoperative spirometry and preoperative and postoperative chest radiography and perfusion lung scanning performed on a routine, unselected basis). An interim analysis of the first 200 patients indicates that low-dose heparin significantly reduces the incidence of calf-vein thrombosis but does not reduce the incidence of proximal segment thrombosis or non-fatal pulmonary embolism. Thus the routine use of low-dose heparin prophylaxis in all major surgical procedures in patients aged over 40 may not be advisable.
Abstract 18240: Poor Sexual Outcome Among Male ICD Patients Who Have Received Shock and Antitachycardia Pacing Therapy
Authors: Pernille Palm Johansen, Ann-Dorthe Zwisler, Jesper Hastrup Svendsen, Selina K Berg
Journal: Circulation (2015)

Purpose: To investigate (i) the prevalence of erectile dysfunction (ED) in male patients with implantable cardioverter defibrillator (ICD), and (ii) the association between ICD, indication, therapy and poor sexual outcome. Methods: This cross-sectional study included male patients with ICD. Inclusion criteria were NYHA I-II. Exclusion criteria were no partner and no known urinary tract diseases. Participants completed the International Index of Erectile Function questionnaire that concerns sexual function and meet psychometric criteria for test reliability and validity. The study was conducted as a postal survey and questionnaires were mailed out to 818 patients from two university hospitals. Data on indication (primary prevention vs secondary prevention) and therapy (shock and antitachycardia pacing ) was collected from local databases. Results: Data from the 370 responders (response rate 45.2 %) were analyzed. Mean age of patients was 63.9 ± 12.1. International Index of Erectile Function total mean score was 39.6 ± 24.2 (scale range 5 to 75, with higher score indicating better function). The Erectile Function domain mean score was 14.5 ± SD 11.5 (Scale range 1 to 30). The Erectile Function domain was distributed between 48.9 % having severe ED, 7.6 % moderate ED, 7.0 % moderate to mild ED, 7.0 % mild ED and 29.5 % having no ED. Age was highly associated with ED (OR 0.91, 95% CI: 0.88-0.93). Adjusted for age, ED was associated with therapy from the ICD (OR 1.84, 95% CI: 1.07-3.2) and primary prevention indication (OR 1.90, 95% CI: 1.19 - 3.06) compared to patients having an ICD on secondary prevention indication. Conclusions: Erectile dysfunction was present in more than 70 % of male patients with ICD and more than 48 % had severe erectile dysfunction, resulting in inability to perform a sexual intercourse. Age, primary prevention indication and therapy from the ICD were all associated with a poor sexual outcome.
MYOMATA CUTIS.
Authors: M. L. HEIDINGSFELD
Journal: JAMA (1907)

Reduplication of the involuntary muscular fibers of the skin to the degree of tumor formation is probably one of the rarest conditions encountered in dermatology, if the limited number of accepted cases thus far reported in the literature is duly considered. It is more rarely encountered if Besnier's<sup>1</sup>commonly accepted classification is observed and those cases which primarily spring from subcutaneous muscular tissue, the dartos, labia, mamma, etc., the so-called dartoic myomata, which are essentially of surgical importance, are properly excluded. Radcliffe Crocker<sup>2</sup>states that his case is the eleventh clearly defined instance in the literature and accords value to the two additional cases of Wolters'<sup>3</sup>doubtful classification. Leslie Roberts<sup>4</sup>asserts in 1900 that his additional case constitutes the fifteenth well defined instance. There have been but few cases reported in recent years, and Huldschinsky<sup>5</sup>maintains that his constitutes the sixteenth additional case. A casual
Therapeutics
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphokines
Authors: Charles A. Dinarello, James W. Mier
Journal: New England Journal of Medicine (1987)

LYMPHOKINES are polypeptide products of activated lymphocytes that participate in a variety of cellular responses, including the regulation of the immune system. They are released in response to antigen, but in contrast to the chemical composition of antibodies, their chemical composition is not determined by that of the stimulating antigen. Lymphokines were originally thought to be produced only by lymphocytes and to communicate with other cells of the immune system. It is now clear that neither the production of lymphokines nor their effects are restricted to lymphoid cells. For these reasons, the term "lymphokine" is yielding to the more general . . .
Virus-like Structures Found In Benign Cells
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Guidance for Hepatitis C Testing
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
苏金单抗持续用于治疗银屑病的疗效
Authors: M. Augustin, D. Thaci, K. Eyerich, A. Pinter, M. Radtke, F. Lauffer, U. Mrowietz, S. Gerdes, D. Pariser, M. Lebwohl, C. Sieder, N. Melzer, K. Reich
Journal: British Journal of Dermatology (2020)

银屑病影响全球至少 1 亿人, 该疾病导致皮肤出现红色鳞状斑块, 病灶可能会覆盖很大身体面积,也可能影响指甲、头皮、手掌和脚底。这可能导致生活质量严重受损。 对于中度至重度疾病患者, 使用称为生物疗法的药物可能会使皮肤完全康复或几乎完全康复。由于银屑病是一种长期疾病, 因此生物疗法的长期疗效对患者很重要。但有些患者最终可能停止对生物治疗的应答, 这意味着药物不再有效。 患者在多大程度上停止应答, 以及继续治疗时后续恢复应答的比率(意味着治疗再次开始有效)是多少, 尚未在个体患者层面进行这些研究。关于药物治疗疾病(其疗效)的持续能力的研究称为药物稳定性研究。 苏金单抗是银屑病的一种许可的生物疗法,其在大型临床试验中显示具有持久的疗效和安全性。在 16 周的治疗期内,苏金单抗治疗可使银屑病减少 90%,而且研究证明长期疗效长达 5 年。 在本研究中,德国和美国的研究人员研究了苏金单抗在参加两项大型临床试验的人群中的应答稳定性。他们发现,在大多数患者中, 苏金单抗的疗效在一年治疗期内保持稳定, 而且苏金单抗继续治疗可使某些患者恢复失去的疗效。持续应答丧失不常见。 患者因素(包括体重、既往生物治疗失败及血浆中的药物水平)可能影响应答的稳定性。 This summary relates to the study: 苏金单抗继续治疗与应答高保留或恢复率有关
Reply
Authors: W Fischbach, J Mossner
Journal: Gut (1988)

Faecal alpha-l-antitrypsin in chronic inflammatory bowel disease SIR,-Fischbach et al' found that patients with chronic inflammatory bowel disease (CIBD) had significantly raised faecal alpha-1-antitrypsin (FAlAT) concentrations compared with controls and other patients with non-inflammatory bowel disorders.Patients with clinically active disease had higher FAlAT's than those with quiescent disease, but the difference was not significant.Clinical disease activity correlated better with ESR, albumin, orosomucoid, serum AlAT, and .'.In labelled granulocyte excretion.Their CIBD patients had lower FAlAT's compared with those we reported2 and by Meyers.3Fischbach et al suggested that this discrepancy could have been because of 'patient selection' rather than a 'technical problem'.They stated that most of their patients were not very ill; the range of disease activity scores was not presented in their paper.Fischbach and colleagues concluded that assess- ment of inflammatory activity can not be solely based upon FAlAT excretion because factors other than mucosal inflammation could result in excessive enteric protein loss.While this might be true, I disagree with some of the author's interpretations of their results.First, in our experience, patients with moderate to severe CIBD have higher FAIAT's.2One would expect lower values for patients, such as described by Fischbach et al, with only mild clinical disease.Second, it is possible that the authors' findings were the result of a technical problem with the assay.The FAlAT concentrations reported in our study2 were generated on now unavailable Calbiochem Behring M-Partigen radial immunodiffusion (RID) plates.Since then our laboratory has had extensive experience in performing this assay on different RID systems.4Other investigators have also reported variation in AIAT values done on different com- mercially available RID plates.5The manufacturer suggests that 20 RI supernatant be placed into the
Vth Perugia Quadrennial International Conference on Cancer
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Vth Perugia Quadrennial International Conference on Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Page 1919, https://doi.org/10.1093/jnci/48.6.1919 Published: 01 June 1972
The advanced glaucoma intervention study (AGIS): 4. comparison of treatment outcomes within race
Journal: Ophthalmology (1998)

The purpose of this report is to present separately for black and white patients with advanced glaucoma 7-year results of two alternative surgical intervention sequences.A randomized controlled trial.A total of 332 black patients (451 eyes), 249 white patients (325 eyes), and 10 patients of other races (13 eyes) participated. Potential follow-up ranged from 4 to 7 years.Eyes were randomly assigned to either an argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy (ATT) sequence or a trabeculectomy-ALT-trabeculectomy (TAT) sequence. The second and third interventions were offered after failure of the first and second interventions, respectively.Average percent of eyes with decrease of visual field (APDVF), average percent of eyes with decrease of visual acuity (APDVA), and average percent of eyes with decrease of vision (APDV) are the outcome measures. Decrease of visual field (DVF) is an increase from baseline of at least 4 points on a glaucoma visual field defect scale ranging from 0 to 20, decrease of visual acuity (DVA) is a decrease from baseline of at least 15 letters (3 lines), and decrease of vision (DV) is the occurrence of either DVF or DVA. The averages are of percent decreases observed at 6-month intervals from the first 6-month visit to the end of the specified observation period.In both black and white patients throughout 7-year follow-up, the mean decrease in intraocular pressure was greater in eyes assigned to TAT, and the cumulative probability of failure of the first intervention was greater in eyes assigned to ATT. In black patients, APDVF, APDVA, and APDV are less for the ATT sequence than for the TAT sequence throughout the 7 years. In white patients, APDVF also favors the ATT sequence but only for the first year, after which it favors the TAT sequence through the seventh year; APDVA also favors the ATT sequence, but the ATT-TAT difference progressively diminishes over 7 years; and APDV favors ATT over TAT initially, but after 4 years, the advantage switches to and remains with TAT.These data support use of the ATT sequence for all black patients. For white patients without life-threatening health problems, the data support use of the TAT sequence.